FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

RAY RUSSELL T
2. Issuer Name and Ticker or Trading Symbol

ALLERGAN INC [ AGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

2525 DUPONT DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)

3/17/2015
(Street)

IRVINE, CA 92612
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   3/17/2015     D    27167   (1) (2) D   (2) 0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Nonemployee Director Stock Option (Right to Buy)   $51.715   3/17/2015     D         9000   (3)   5/2/2007   5/2/2016   Common Stock   9000   $0   0   D    
Nonemployee Director Stock Option (Right to Buy)   $60.60   3/17/2015     D         11400   (4)     (5) 5/1/2017   Common Stock   11400   $0   0   D    
Nonemployee Director Stock Option (Right to Buy)   $54.32   3/17/2015     D         11400      (5) 5/6/2018   Common Stock   11400   $0   0   D    
Nonemployee Director Stock Option (Right to Buy)   $46.66   3/17/2015     D         11400      (5) 4/30/2019   Common Stock   11400   $0   0   D    
Nonemployee Director Stock Option (Right to Buy)   $61.98   3/17/2015     D         11400      (5) 4/29/2020   Common Stock   11400   $0   0   D    
Nonemployee Director Stock Option (Right to Buy)   $166.32   3/17/2015     D         4305      (5) 5/6/2024   Common Stock   4305   $0   0   D    

Explanation of Responses:
( 1)  Pursuant to that certain Agreement and Plan of Merger dated November 16, 2014, (the "Merger Agreement") by and among the Issuer, Actavis, Plc ("Actavis) and a wholly-owned subsidiary of Actavis, the Issuer became an indirect wholly-owned subsidiary of Actavis upon consummation of the merger (the "Effective Date"). Each share of common stock was disposed of in exchange for $129.22 cash plus 0.3683 of an Actavis ordinary share, having a market value of $307.51 per share on the Effective Date.
( 2)  The number of shares reported on this line item includes shares acquired pursuant to dividend rights attached to restricted stock units that were previously granted and reported as Table 1, Non-Derivative Securities.
( 3)  The option was previously reported as covering 4,500 shares at an exercise price of $103.43. The issuer effected a two-for-one stock split on June 22, 2007, which resulted in 9,000 shares held by the reporting person at an exercise price of $51.7150.
( 4)  The option was previously reported as covering 5,700 shares at an exercise price of $121.20. The Issuer effected a two-for-one stock split on June 22, 2007, which resulted in 11,400 shares held by the reporting person at an exercise price of $60.60.
( 5)  Each option vested in full on the Effective Date and was cancelled in exchange for a cash payment equal to the number of shares subject to the option immediately prior to the merger, multiplied by the difference between (i) 0.3683 times $294.1509 (which represents the 10-day volume weighted average price of Actavis stock starting on the 11th trading day prior to the closing) plus $129.22 and (ii) the exercise price of the option, subject to the applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
RAY RUSSELL T
2525 DUPONT DRIVE
IRVINE, CA 92612
X



Signatures
/s/ Matthew J. Maletta, Attorney-in-Fact for Russell T. Ray 3/19/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Allergan (NYSE:AGN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Allergan Charts.
Allergan (NYSE:AGN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Allergan Charts.